Market Capitalization

Mackenzie Investments' 2026 forecast warns of fewer Fed cuts than expected, highlighting opportunities in AI-driven equities and strategic commodities.

With blockbuster sales from VYJUVEK, Krystal Biotech heads to J.P. Morgan with investors eager for news on its global growth and ambitious pipeline.

Prenetics slashed future dilution risk by exchanging 4.7M warrants, a move analysts see as crucial for fueling the rapid growth of its IM8 wellness brand.

Gyre Therapeutics secures a pivotal conditional approval pathway in China for its novel liver fibrosis drug, offering hope for millions of hepatitis B patients.

Occidental nets $9.7B from its OxyChem sale to Berkshire Hathaway, pivoting to oil and carbon capture while retaining significant environmental liabilities.

New ETFs boast yields up to 99%, but a closer look at their complex options strategy reveals significant risks of capital erosion for unwary investors.

Genelux appoints Dr. Jason Litten as CMO, a strategic move to steer its promising oncolytic virus, Olvi-Vec, through crucial late-stage cancer trials.

Fresh off a major drug approval, Insmed's upcoming J.P. Morgan talk is under scrutiny as investors eye pipeline updates and acquisition potential.

Following the sale of its legacy business, the newly-rebranded Accendra Health launches on the NYSE with a laser focus on the booming home healthcare market.

All eyes are on Sandisk's Jan 29 report. Can the reborn flash memory leader meet lofty expectations and prove its post-spin-off strategy is a success?

Peruvian financial giant Credicorp is buying Florida's Helm Bank, a strategic move to capture the lucrative cross-border wealth of Latin American clients.

New York's Peripherii launches Priamble™, audio earrings blending luxury jewelry with open-ear tech. Is this the future of wearable sound for women?

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

A successful demonstration of Revoltz's compact electric cargo vehicle to Israeli officials could signal a major shift in last-mile logistics.

Verizon's Q4 report will reveal if its FWA growth can offset mobile pressures and prove the new CEO's strategy is paying off for investors and customers.

The AI investment frenzy is shifting from GPUs to the physical world of power, cooling, and real estate, creating a new class of high-value companies.

With $13.2 billion in assets and 3.41% of all ETH, Bitmine is on a quest for market dominance. A crucial shareholder vote will decide its future.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

EUDA Health's new Helixé 2.0 supplement boasts enhanced potency, nano-delivery tech, and Halal certification to capture the booming global wellness market.

A major acquisition turned sour, a 25% stock crash, and now a class action lawsuit. Inside Perrigo's costly infant formula venture and what it means.